Vaxcyte (PCVX) Earnings Date & Reports

Key Takeaways

• Vaxcyte is expected to report third-quarter 2026 results in early November, with consensus estimates pointing to a net loss of roughly $2.14 per share.
• As a clinical-stage vaccine developer, Vaxcyte generates no meaningful product revenue, so the focus is on spending, cash runway, and pipeline updates rather than top-line sales.
• Investors are watching for updates on VAX-31, the lead pneumococcal conjugate vaccine (PCV) candidate, ahead of the OPUS-1 Phase 3 topline readout expected in the fourth quarter of 2026.
• Heavy spending tied to Phase 3 trials and manufacturing scale-up has widened quarterly losses throughout 2026.
• Cash, cash equivalents, and investments totaled $2,741.2 million as of March 31, 2026, supporting the clinical pipeline.

Earnings Context and Why It Matters

Vaxcyte (NASDAQ: PCVX) is a clinical-stage biotechnology company developing conjugate and protein-based vaccines for bacterial infectious diseases, including pneumococcal disease and Group A Streptococcus. Because the company is pre-revenue, its quarterly results are a window into how efficiently management is deploying capital across a rapidly expanding late-stage pipeline. With the pivotal OPUS-1 trial for VAX-31 nearing a topline readout, this earnings report matters less for profit and loss than for what management signals about trial timelines, manufacturing readiness, and the pace of cash burn ahead of a potential commercial launch.

Earnings Expectations

Analysts expect Vaxcyte to report a net loss of approximately $2.14 per share for the third quarter of 2026, according to consensus estimates, though individual projections range from a loss of about $1.67 to $2.70 per share. Because Vaxcyte has no approved product on the market, revenue is not a meaningful metric for this quarter; instead, investors will scrutinize research and development (R&D) expenses, which climbed to $312.8 million in the first quarter of 2026, and general and administrative (G&A) costs.

For context, Vaxcyte posted a narrower-than-expected loss of $1.97 per share in the second quarter of 2026, beating the consensus estimate of about $2.06. That followed a first-quarter 2026 loss of $2.30 per share, which missed expectations of roughly $1.78 and contributed to a notable single-day decline in the stock. The widening quarterly losses reflect the ramp-up of VAX-31's OPUS Phase 3 program and pre-commercial manufacturing activities rather than any operational setback.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical complement to fundamental research on names like Vaxcyte. Explore the AI Screener to refine your watchlist and identify potential setups across the biotech sector and beyond.

Market Reaction and Investor Sentiment

Sentiment heading into Vaxcyte's third-quarter report is closely tied to the OPUS-1 data readout expected later in the fourth quarter. Historically, the stock has shown sensitivity to earnings surprises: it rose modestly after the narrower second-quarter loss but fell sharply, roughly 10%, following the wider first-quarter miss. For a pre-revenue biotech, investors tend to weigh trial catalysts more heavily than headline per-share figures, so a stable cash position and a reaffirmed OPUS-1 timeline could matter more to the stock than the exact size of the quarterly loss. Key risk factors include accelerating cash burn, any delays to pivotal readouts, and the possibility of future financing needs.

Forward Outlook and Key Factors to Monitor

The central event on Vaxcyte's horizon is the topline safety, tolerability, and immunogenicity data from the OPUS-1 Phase 3 pivotal noninferiority trial, which management has guided to the fourth quarter of 2026. This readout will be a defining catalyst for the VAX-31 adult program and for how investors frame the company's path toward regulatory filings.

Beyond OPUS-1, the company expects topline data from the OPUS-2 and OPUS-3 Phase 3 trials in the first half of 2027, along with results from the VAX-31 infant Phase 2 dose-finding study by the end of that same period. A Phase 1 adult study for VAX-A1, targeting Group A Streptococcus, was also slated to begin in mid-2026.

Investors should also monitor operating expense trends, particularly R&D spending, and the status of manufacturing and supply-chain buildout with partner Lonza, which underpins potential global commercial capacity. Given the scale of ongoing investment, cash runway and any commentary on future financing will remain important watch points alongside the clinical catalysts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations